PMID- 38523597
OWN - NLM
STAT- MEDLINE
DCOM- 20240410
LR  - 20240422
IS  - 2410-8650 (Electronic)
IS  - 1607-551X (Linking)
VI  - 40
IP  - 4
DP  - 2024 Apr
TI  - CircITGA7 regulates malignant phenotypes in bladder cancer cells via targeting 
      miR-330-3p/KLF10 axis.
PG  - 324-334
LID - 10.1002/kjm2.12821 [doi]
AB  - Bladder cancer (BCa) is one of the common malignancies. Circular RNAs (circRNAs) 
      play regulatory roles in cancer progression. CircITGA7 is a circRNA generated 
      from several exons of ITGA7. The potential role of circITGA7 in BCa remains 
      unknown and needs to be explored. Quantitative real time polymerase chain 
      reaction (qRT-PCR) was used to assess circITGA7 and miR-330-3p expression in BCa 
      tissues and cell lines. Kaplan-Meier analysis was used to evaluate the overall 
      survival of these BCa patients. The biological function of circITGA7 was examined 
      by overexpression of circITGA7 using CCK-8, EdU, wound-healing, and Transwell 
      assays. Xenograft assay was performed to further validate the in vitro results. 
      To explore the mechanism of circITGA7, luciferase reporter, RNA pull-down, 
      fluorescence in situ hybridization (FISH) assays were employed to examine the 
      binding interaction among circITGA7, miR-330-3p and kruppel-like factor 10 
      (KLF10). Western blot was used to study the protein levels of KLF10.CircITGA7 was 
      downregulated in BCa tissues and cell lines and indicated longer overall 
      survival. Moreover, circITGA7 restricted cell proliferation, migration and 
      invasion of BCa through negatively regulating miR-330-3p. The in vivo model 
      showed that circITGA7 influenced the tumor growth. Besides, the overexpression of 
      miR-330-3p promoted cell progression by directly targeting KLF10. 
      Mechanistically, circITGA7 inhibited BCa progression by activating KLF10 via 
      targeting miR-330-3p.CircITGA7 alleviates BCa cell progression via 
      circITGA7/hsa-miR-330-3p/KLF10 axis, which may provide novel therapeutic targets 
      for BCa.
CI  - (c) 2024 The Authors. The Kaohsiung Journal of Medical Sciences published by John 
      Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical University.
FAU - Yang, Xian-Xu
AU  - Yang XX
AD  - Department of Urology, The First Affiliated Hospital of Jinzhou Medical 
      University, Jinzhou, China.
FAU - Wang, Chao
AU  - Wang C
AUID- ORCID: 0009-0005-1025-8720
AD  - Department of Urology, The First Affiliated Hospital of Jinzhou Medical 
      University, Jinzhou, China.
LA  - eng
GR  - 2023-BS-199/Natural Science Foundation Project of Liaoning Province/
PT  - Journal Article
DEP - 20240325
PL  - China (Republic : 1949- )
TA  - Kaohsiung J Med Sci
JT  - The Kaohsiung journal of medical sciences
JID - 100960562
RN  - 0 (Early Growth Response Transcription Factors)
RN  - 0 (KLF10 protein, human)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (MicroRNAs)
RN  - 0 (MIRN330 microRNA, human)
RN  - 0 (RNA, Circular)
RN  - 0 (integrin alpha7)
SB  - IM
MH  - Humans
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Early Growth Response Transcription Factors/genetics/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - In Situ Hybridization, Fluorescence
MH  - Kruppel-Like Transcription Factors/genetics
MH  - *MicroRNAs/genetics/metabolism
MH  - Phenotype
MH  - RNA, Circular/genetics
MH  - *Urinary Bladder Neoplasms/pathology
OTO - NOTNLM
OT  - KLF10
OT  - bladder cancer
OT  - circITGA7
OT  - miRNA sponge
OT  - miR-330-3p
EDAT- 2024/03/25 06:42
MHDA- 2024/04/10 06:43
CRDT- 2024/03/25 04:13
PHST- 2024/01/14 00:00 [revised]
PHST- 2023/08/31 00:00 [received]
PHST- 2024/01/29 00:00 [accepted]
PHST- 2024/04/10 06:43 [medline]
PHST- 2024/03/25 06:42 [pubmed]
PHST- 2024/03/25 04:13 [entrez]
AID - 10.1002/kjm2.12821 [doi]
PST - ppublish
SO  - Kaohsiung J Med Sci. 2024 Apr;40(4):324-334. doi: 10.1002/kjm2.12821. Epub 2024 
      Mar 25.